

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited

三愛健康產業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

POSITIVE PROFIT ALERT

This announcement is made by Sanai Health Industry Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) of the Company and potential investors that, based on the latest available information and the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021, the Group is expected to record a gross profit of not less than RMB16 million for the six months ended 30 June 2021, as compared to approximately RMB12 million for the corresponding period in 2020 and to record a net profit attributable to the shareholders of the Company of approximately RMB6 million for the six months ended 30 June 2021 as compared to approximately RMB2 million for the corresponding period in 2020. The increase in gross profit and net profit attributable to the shareholders of the Company for the six months ended 30 June 2021 was mainly attributable to (i) the increase in sales of self-produced pharmaceutical products with relatively high gross profit margin; and (ii) a drop in the distribution costs, administrative and other expenses due to the significant reduction in the operation of other general trading business.

As the Company is still in the process of preparing and finalising the interim results of the Group for the six months ended 30 June 2021, information contained in this announcement is only based on a preliminary assessment by the Company’s management team with reference to the information currently available to the Company and the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021, which has not been audited or reviewed by the Company’s auditor or the audit committee of the Company and may therefore be subject to adjustments.

Shareholders and potential investors should carefully read the Company's interim results announcement for the six months ended 30 June 2021, which is expected to be published in late August 2021.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on Friday, 24 January 2020 and will remain suspended until the Company fulfills the resumption conditions.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sanai Health Industry Group Company Limited
Chen Chengqing
Chairman

Hong Kong, 17 August 2021

As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing (Chairman), Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Mr. Zhang Ruigen.